RE:RE:RE:RE:More comments on Biogen's aducanumab I agree too. Development of anti-amyloid as a class would be good for PMN, too bad that Elliot chose to go instead with "first in class vs best in class" which means by default the class becomes Aducanumab-like, and therefore fails-like-Aducanumab. Elliot, please, it's not too late to reposition from this other equally simplified concept.